Chai Discovery vs EvolutionaryScale
The two best governed companies in protein design, which matters because this is the one category in the index where the governance question is biosecurity rather than bias. EvolutionaryScale published its flagship model in a major peer reviewed journal, offers the widest access routes including holding the weights yourself, and publishes the most substantive position anywhere here on the risk that designing novel proteins creates. Chai releases named, versioned models with a documented history, quantifies its wet laboratory validation including how many targets were attempted and how many designs tested, and backs its governance position with a costly action rather than a statement. Both are unusually open for this field. Neither has a therapeutic established in humans, so read the excellent molecular evidence as exactly that.
- Models are named, versioned and released publicly with a documented history, and the underlying method is described specifically rather than as generative machine learning.
- Wet laboratory validation is quantified with its design stated, including how many targets were attempted and how many designs tested.
- The governance posture is the most complete in this category and is backed by a costly action rather than a policy statement.
- The flagship model appears in a major peer reviewed journal, so the method passed external review rather than a demonstration.
- The widest access in this category and the only route where a user can hold the weights, which changes the dependency entirely.
- It publishes a substantive position on the biosecurity risk that designing novel proteins creates, rather than generic principles.
Side by Side
| Axis | C Chai Discovery |
E EvolutionaryScale |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
These two hold the strongest governance positions in a category where the governance question is biosecurity rather than bias, and that is the axis to compare them on rather than benchmark performance. Neither holds a located security attestation. Molecular evidence and clinical evidence are different things on both records: excellent laboratory validation exists and no therapeutic from either has been established in humans, so neither should be read as a clinical stage proposition. Neither publishes pricing, and the access models differ enough that a commercial comparison requires knowing which route you intend to take.